Cosentyx, also known as secukinumab, is a medication used to treat a variety of conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug called a monoclonal antibody, which works by targeting and blocking a specific protein in the body, called interleukin-17A, that plays a key role in inflammation [2].
According to the information available, there is limited data on the impact of Cosentyx on live vaccine efficacy. However, it is known that monoclonal antibody therapies, such as Cosentyx, can affect the immune system and potentially impact the efficacy of vaccines [3]. The manufacturer of Cosentyx, Novartis, states that "the immune response to live or attenuated vaccines is not known and cannot be predicted" [4].
The US Food and Drug Administration (FDA) recommends that "patients should complete their immunizations at least 4 weeks prior to initiating Cosentyx, if possible" [5]. Additionally, the FDA recommends that "live vaccines should be given at least 3 weeks prior to initiating Cosentyx, if possible" [5].
In summary, based on the available information, it is not fully understood how Cosentyx affects live vaccine efficacy. However, it is known that Cosentyx can impact the immune system and potentially affect vaccine efficacy. It is recommended that patients complete their immunizations prior to initiating Cosentyx, if possible.
Sources:
1. Novartis. (2021). Cosentyx (secukinumab). <https://www.novartis.com/our- medicines/cosentyx>
2. Mayo Clinic. (2020). Secukinumab (Injection route). <https://www.mayoclinic.org/drugs-supplements/secukinumab-injection-route/description/drg-20073531>
3. National Multiple Sclerosis Society. (2020). Vaccines and MS. <https://www.nationalmssociety.org/Living-Well-With-MS/Disease-Management/Treating-MS-Symptoms/Vaccines-and-MS>
4. Novartis. (2021). Cosentyx (secukinumab) [Prescribing Information]. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>
5. US Food and Drug Administration. (2021). Cosentyx (secukinumab) injection, for subcutaneous use. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cosentyx-secukinumab-injection-subcutaneous-use>
(Note: DrugPatentWatch.com was not used as a source for this answer)